Amygdala neuronal dyshomeostasis via 5‐HT receptors mediates mood and cognitive defects in Alzheimer's disease.

Autor: Wu, Xin‐Rong¹ (AUTHOR), Zhu, Xiao‐Na² (AUTHOR), Pan, Yuan‐Bo³ (AUTHOR), Gu, Xue² (AUTHOR), Liu, Xian‐Dong^1,2 (AUTHOR), Chen, Si² (AUTHOR), Zhang, Yu² (AUTHOR), Xu, Tian‐Le² (AUTHOR), Xu, Nan‐Jie^2,4,5,6 (AUTHOR) xunanjie@sjtu.edu.cn, Sun, Suya¹ (AUTHOR) sunsuya@shsmu.edu.cn

Publikováno v: Aging Cell. Aug2024, Vol. 23 Issue 8, p1-18. 18p.

Recovery of 5-HT 1A receptors after irreversible blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)

Autor: Bolaños-Jiménez, Francisco, Schechter, L E, Laporte, Anne Marie, Hamon, Michel, Gozlan, Henry

Publikováno v: Proceedings-Western Pharmacology Society
Proceedings-Western Pharmacology Society, [Western Pharmacology Society]; 1998, 1991, 34, pp.387-393
Proceedings-Western Pharmacology Society, 1991, 34, pp.387-393

International audience

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::26d8673fb9714681885c029e9e9e2b7d
https://hal.inrae.fr/hal-02708343

Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies

Autor: Schechter, L E, Bolaños-Jiménez, Francisco, Gozlan, Henry, Lanfumey, L, Haj-Dahmane, S, Laporte, Anne Marie, Fattaccini, C M, Hamon, Michel

Publikováno v: Journal of Pharmacology and Experimental Therapeutics
Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, 1990, 255 (3), pp.1335-1347
Journal of Pharmacology and Experimental Therapeutics, 1990, 255 (3), pp.1335-1347

International audience; Inasmuch as sustained treatment with the 5-hydroxytryptamine1A (5-HT1A) agonist, ipsapirone, is necessary for inducing anxiolytic and antidepressant effects in the clinic, investigations were performed for assessing the possib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d77c9eeca39327b14cfda90548551f71
https://hal.inrae.fr/hal-02711946

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.

Autor: Beyer, C. E., Lin, Q., Platt, B., Malberg, J., Hornby, G., Sullivan, K. M., Smith, D. L., Lock, T., Mitchell, P. J., Hatzenbuhler, N. T., Evrard, D. A., Harrison, B. L., Magolda, R., Pangalos, M. N., Schechter, L. E., Rosenzweig-Lipson, S., Andree, T. H.

Publikováno v: British Journal of Pharmacology; May2009, Vol. 157 Issue 2, p307-319, 13p, 5 Charts, 5 Graphs